PIQUR Therapeutics

PIQUR Therapeutics, Pierre Fabre partner in dermato-oncology

Thursday, January 12, 2017

PIQUR Therapeutics, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, the second largest private French pharmaceutical group, have signed a collaboration agreement for the development of PIQUR’s lead compound PQR309 in dermato-oncology. The exclusive deal will see PIQUR and Pierre Fabre’s R&D teams work together on the evaluation and development of dermatological formulations of PI3K/mTOR inhibitors across multiple therapeutic indications. 

[Read More]